Gene · 950
NIH grants835
NIH grants whose papers are about the gene, through NIH's grant-paper links.
241 to 260 of 835
Download this page as JSON| Grant | Title | SCARB2 papers | Newest fiscal year |
|---|---|---|---|
| U01AG046139 | A Systems Approach to Targeting Innate Immunity in AD | 2 | 2022 |
| F30HL151048 | Identification of structural features of SR-BI that facilitate HDL-cholesterol clearance | 1 | 2022 |
| K08AR072791 | Molecular control of CD4 T cell ability to help B cells | 1 | 2022 |
| P30DK079310 | George M. O'Brien Kidney Center at Yale | 1 | 2022 |
| P50NS108675 | Innate and Adaptive Immunity in Parkinson Disease | 1 | 2022 |
| R01AI049424 | Development of Paratransgenic Ticks for Disease Control | 1 | 2022 |
| R01AI140539 | Defining the functional interface between the ER and flaviviruses | 1 | 2022 |
| R01CA223828 | Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer | 1 | 2022 |
| R01DK115474 | Ion channels in the tubulovesicles | 1 | 2022 |
| R01ES029280 | Environmental Exposures, AHR Activation, and Placental Origins of Development | 1 | 2022 |
| R01GM105718 | Molecular mechanisms that match lysosome function to cellular demand | 1 | 2022 |
| R01GM129327 | Signal Propagation in Protein Allostery: Mechanism and Evolution | 1 | 2022 |
| R01NS102257 | Role of presynaptic targeting of alpha-synuclein in the pathogenesis of Parkinson's Disease and Dementia with Lewy Bodies | 1 | 2022 |
| R01NS105971 | Molecular mechanisms of Progranulin in Neurodegeneration | 1 | 2022 |
| R01NS107404 | The role of NOD2/RIPK2 signaling in the pathogenesis of Parkinson's Disease | 1 | 2022 |
| R01NS108296 | Cognitive Deficits After Experimental Febrile Seizures: Neurobiology & Biomarkers | 1 | 2022 |
| R01NS108765 | Mechanisms of Cognitive Impairment Following Early-Life Seizures | 1 | 2022 |
| R21HD104071 | A new animal model for investigating the invasive trophoblast lineage | 1 | 2022 |
| R35HL135824 | Using Genetics to Inform Mechanism of Cardiovascular Disease | 1 | 2022 |
| RF1AG066107 | Epidemiological Integration of Genetic Variants and Metabolomics Profiles in Washington Heights Columbia Aging Project | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/950/grants?page=13